Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nitroanilide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.38 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.38 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitroanilide SCHEMBL3094185 | 1.00 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL5718352 | 0.97 | L3MBTL1 (0.50) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL6001 | 0.97 | L3MBTL1 (0.50) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL28530795 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL29021277 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL28115452 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL30436028 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL4541850 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL20876421 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 | |
| Nitroanilide SCHEMBL29195338 | 0.95 | L3MBTL1 (0.48) | L3MBTL1ALOX12HPGDALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4507716-A1 | METHODS OF PREPARING ALBUMIN PREPARATIONS | CSL Behring LLC (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023200908-A1 | METHODS OF PREPARING ALBUMIN PREPARATIONS | CSL BEHRING LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-108424474-B | Deanticoagulated heparin derivatives and their use in the treatment of inflammatory bowel disease | 清华大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-115541513-A | Method for detecting plasmin content in dairy product | 新希望乳业股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3016971-A1 | COMPOSITIONS AND METHODS FOR INHIBITING THROMBOGENESIS | National University of Singapore (SG) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015002611-A9 | COMPOSITIONS AND METHODS FOR INHIBITING THROMBOGENESIS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-02-25 | — | — | WO | disclosed |
| WO-2015002611-A1 | COMPOSITIONS AND METHODS FOR INHIBITING THROMBOGENESIS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2015-01-08 | — | — | WO | disclosed |
| WO-2007050072-A1 | SALIVA TEST FOR HEMOLYTIC STREPTOCOCCUS | MOSHER LEROY E (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-1995002066-A1 | METHOD FOR INHIBITING PROCOAGULANT HLA-DR OF MELANOMA CELLS | BIOMIDE INVESTMENT LIMITED PARTNERSHIP (US) | 1995-01-19 | — | — | WO | disclosed |
| WO-1989009817-A1 | COMPOSITION AND METHOD FOR ACCELERATION OF CLOT LYSIS | THE GENERAL HOSPITAL CORPORATION (US) | 1989-10-19 | — | — | WO | disclosed |
| EP-0336693-A2 | Acceleration of clot lysis | THE GENERAL HOSPITAL CORPORATION (US) | 1989-10-11 | — | — | EP | disclosed |